-
Cancer & Tumour Suppressors – Mini Review(Post)
Cancer DevelopmentCancer is a group of diseases that involves abnormal cell growth resulting in malignant tumours/ malignant neoplasms. Cancer is a leading cause of morbidity, with 14 million ne
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Inebilizumab: Advancing Research and Clinical Applications(Post)What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
Metabolic Bloodhounds: Engineering Immune Cells to Track Cancer's Chemical Trail(Post)Imagine a specialized squad of immune cells, meticulously trained and equipped, not just to fight cancer, but to sniff it out by its unique metabolic scent. This isn't science fiction; it's the groun
Flow Cytometry Protocol | 10 Hints & Tips(Post)Lab Methods · Flow CytometryFlow Cytometry Protocol: Two Worked Protocols, Controls and 10 Practical TipsFlow cytometry measures individual cells in a fluid stream at hundreds per second, reporting si
Valider en labo vos anticorps pour western blot : testez 2–3 dilutions(Post)Valider en labo vos anticorps pour western blot : testez 2–3 dilutions Pour un Western blot fiable, choisissez un anticorps validé sur des lysats biologiques pertinents, plutôt qu’un anticorps choisi
AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
CXCL16 – Review(Post)CXCL16 CXCL16, a unique member of the CXC chemokine family, stands at the crossroads of immune modulation and vascular biology. Initially discovered as a chem
Antibody Seroconversion Response in COVID-19(Post)Seroconversion Implications in SARS-CoV-2 Diagnostic Testing Key Points: COVID-19, the pandemic
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
TIM-3/Gal-9 Pathway in Antiparasitic Immunity(Post)Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including
How to Choose a Secondary Antibody(Post)The selection of a secondary antibody is a critical step in the experimental design of various immunodetection methods, including Western Blot, ELISA, immunohistochemistry (IHC), and immunofluores
Sensing Danger: The Biology of TLR-Mediated Inflammation(Post)By Eoin Mac Réamoinn Toll-like receptors (TLRs) are renowned for their fundamental roles in innate sensing and initiating inflammatory responses. TLRs acco
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Reprogramming Regulatory T Cells: A Breakthrough in Cancer Immunotherapy(Post)A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and r
T cell Immunophenotyping - A Guide(Post)Immunology · Flow CytometryT Cell Immunophenotyping: Markers, Subsets and Panel DesignImmunophenotyping identifies cell populations by the proteins on their surface. For T cells that means resolving n